Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ligand Pharmaceuticals (LGND) Total Non-Current Liabilities (2016 - 2025)

Historic Total Non-Current Liabilities for Ligand Pharmaceuticals (LGND) over the last 16 years, with Q3 2025 value amounting to $506.7 million.

  • Ligand Pharmaceuticals' Total Non-Current Liabilities rose 50453.98% to $506.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $506.7 million, marking a year-over-year increase of 50453.98%. This contributed to the annual value of $81.2 million for FY2024, which is 3864.89% up from last year.
  • Ligand Pharmaceuticals' Total Non-Current Liabilities amounted to $506.7 million in Q3 2025, which was up 50453.98% from $105.7 million recorded in Q2 2025.
  • In the past 5 years, Ligand Pharmaceuticals' Total Non-Current Liabilities registered a high of $520.6 million during Q1 2021, and its lowest value of $57.7 million during Q3 2023.
  • Moreover, its 5-year median value for Total Non-Current Liabilities was $137.4 million (2022), whereas its average is $214.8 million.
  • Per our database at Business Quant, Ligand Pharmaceuticals' Total Non-Current Liabilities plummeted by 7284.77% in 2023 and then surged by 50453.98% in 2025.
  • Over the past 5 years, Ligand Pharmaceuticals' Total Non-Current Liabilities (Quarter) stood at $454.7 million in 2021, then tumbled by 69.78% to $137.4 million in 2022, then crashed by 57.4% to $58.5 million in 2023, then soared by 38.65% to $81.2 million in 2024, then skyrocketed by 524.22% to $506.7 million in 2025.
  • Its Total Non-Current Liabilities stands at $506.7 million for Q3 2025, versus $105.7 million for Q2 2025 and $95.7 million for Q1 2025.